SIA
IBER.U

Schechter Investment Advisors’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Schechter Investment Advisors’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-175,562
Closed -$1.75M – 883
2022
Q4 		$1.75M Sell
175,562
-1,600
-0.9% -$16K 0.16% 141
2022
Q3 		$1.76M Sell
177,162
-900
-0.5% -$8.91K 0.17% 122
2022
Q2 		$1.75M Sell
178,062
-5,420
-3% -$53.4K 0.17% 116
2022
Q1 		$1.8M Sell
183,482
-27,210
-13% -$271K 0.17% 122
2021
Q4 		$2.11M Buy
+210,692
New +$2.1M 0.19% 109

Schechter Investment Advisors's IBER.U Position: Q1 2023 in Review

Schechter Investment Advisors sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q1 2023, closing a stake of 175,562 shares — an estimated $1.75M sold.

Schechter Investment Advisors first reported a position in IBER.U in Q4 2021 and held it in 5 quarters. The position peaked at $2.11M in Q4 2021. 0 funds tracked by Wall St. Rank hold IBER.U as of Q1 2023.

  • Schechter Investment Advisors reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q1 2023 after selling out during the quarter.
  • Schechter Investment Advisors sold 175,562 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q1 2023, an estimated $1.75M.
  • Schechter Investment Advisors first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q4 2021 and held it in 5 quarters.
  • Schechter Investment Advisors's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $2.11M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q1 2023.

Based on Schechter Investment Advisors's 13F filing for Q1 2023, filed 28 Apr 2023.